American Diversified Holdings Corporation (ADHC) to Acquire GlucoGuard, a AI-Based Medical Device for Managing Nocturnal Hypoglycemia in Diabetic Patients
GlucoGuard Founder Zachary Smith to Join ADHC as Scientific Advisor
Del Mar, California--(Newsfile Corp. - September 9, 2024) - American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce the acquisition of GlucoGuard, a revolutionary AI-driven medical device technology from IMD Solutions, Phoenix, AZ. GlucoGuard is designed to address the critical challenge of managing nocturnal Hypoglycemia for diabetic patients, offering a breakthrough in non-invasive, continuous glucose monitoring and delivery.
In addition to the acquisition, GlucoGuard's founder, Zachary Smith, BS/MS Biomedical Engineering (Arizona State University), will join ADHC's advisory board. Smith will work alongside Bill Colone, a renowned expert in biomedical solutions, to advance GlucoGuard's development and integration into ADHC's expanding healthcare technology portfolio.
The terms of the acquisition remain undisclosed, but financing is expected to be non-dilutive.
Transforming Diabetes Management
Zachary Smith commented, "ADHC provides the ideal platform for the commercialization of GlucoGuard. Both Bill and I are eager to bring this life-saving technology to market, helping millions of diabetic patients-both adults and children-better manage their glucose levels with greater safety and ease."
Bill Colone added, "Hypoglycemia, particularly during sleep, is a persistent and dangerous issue for diabetic patients, often leading to serious consequences like the dreaded 'Death in Bed' syndrome. GlucoGuard's technology offers a game-changing solution to this pressing problem."
Key Development Partnerships
The GlucoGuard system is being developed in collaboration with three key partners:
A leading U.S. research university.
A highly respected biomedical and defense engineering firm.
A top publicly traded company in the Continuous Glucose Monitoring (CGM) sector.
Further details on these collaborations will be disclosed soon.
Cutting-Edge Technology for Unmet Medical Needs
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.
"The GlucoGuard invention is a significant leap forward in addressing one of the most dangerous complications of diabetes," said ADHC management. "We are thrilled to welcome Zachary Smith and his innovative team to ADHC, and we're committed to fast-tracking the development and commercialization of this much-needed technology."
About Artificial Intelligence and Health Care
A recent report from the Mayo Clinic identified three potential benefits of AI in healthcare:
Improving outcomes for both patients and clinical teams.
Lowering healthcare costs.
Benefitting population health.
From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today. Two examples are Preventive Health Care and Risk Assessment.
Cancer Screenings that use radiology can leverage AI to help produce results faster. A noted example is analyzing kidney images in a laborious 45minute process. AI automated process can reduce this analysis to minutes, saving time, money and giving a more accurate diagnosis.
Pre-diabetes patients with no notable symptoms can be screened using AI to determine which type of diabetes they are at risk for and begin preventative care.
The diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, underscoring the vast potential for GlucoGuard's adoption.
The Continuous Glucose Monitoring (CGM) sector, valued at $6.8 billion, further emphasizes the critical demand for advanced glucose management solutions.
IMD Solutions, Inc. is a Nevada-based medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, IMD Solutions is at the forefront of diabetes management technology.
John Cacchioli, CEO American Diversified Holdings Corporation Telephone: (212) 537-5900 Email: [email protected]
Social Media: TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC.
SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
